Amgen Inc (AMGN)
A research Signal Score of unusual activity and the signals behind it. Not advice, not a prediction, not yet backtested.
Our last 30 days of resolved calls came true 33% of the time.See the track record →
Figures reflect the most recent reported period. Margins, ROE and growth are percentages; Debt/Equity and Current ratio are ratios.
A generic 2:1 reward-to-risk example (about a 10% stop and 20% target). Illustrative and educational, not advice. Set your own levels for your risk tolerance.
- 12-month trend+35% over the past year+3
- 52-week positionAbove the midpoint of its 52-week range+9
- QualityStrong net margin (23%)+7
- VolumeNo intraday volume on the free data tier — this factor is disabled, not faked.+0
Score uses live volume/momentum/breakout signals today; insider buying, short interest, options flow and social velocity layer in as those sources come online. How it works →
🤖 The dominant catalyst here is product/pipeline momentum, with Amgen's KRAS inhibitor and broader pipeline news outweighing the modest sale-leaseback and general analyst commentary. Given the mixed but generally constructive news flow, there's a moderate probability—roughly 40–55%—that the recent move continues over the next few weeks, though biotech sentiment and macro factors could easily shift that. Informational only — not financial advice.
- Take the Zacks Approach to Beat the Markets: Bloom Energy, Microsoft & Amgen in FocusYahoo · 2026-09-28
- KRAS Inhibitor Market Projected to Reach $7.8 Billion by 2034Yahoo · 2026-09-28
- Why Amgen’s Pipeline Just Got More InterestingYahoo · 2026-09-27
- Amgen (AMGN) Sells its Deerfield Campus for $151 Million and Leases it BackYahoo · 2026-09-27
- Innovation Is Driving a New Bull Market in Biotech. 16 Ways to Play It, From Our Roundtable Experts.Yahoo · 2026-09-27
Any AI summary is an interpretation of public news, not advice or a price target.